Welcome to our dedicated page for Point Biopharma Global news (Ticker: PNT), a resource for investors and traders seeking the latest updates and insights on Point Biopharma Global stock.
POINT Biopharma Global Inc. (PNT) delivers targeted radiopharmaceutical therapies for cancer treatment, with its pending acquisition by Eli Lilly marking a significant evolution in precision oncology. This page provides essential updates on clinical developments, regulatory milestones, and corporate strategy for investors tracking PNT's innovative radioligand pipeline.
Access timely announcements about 177Lu-PNT2002 clinical progress, manufacturing expansions, and partnership developments. Our curated news collection features earnings reports, trial data publications, and acquisition-related disclosures – all critical for understanding PNT's position in the evolving radiopharmaceutical sector.
Key updates include the Phase 3 SPLASH study outcomes for metastatic prostate cancer treatment and strategic moves following the $1.4 billion acquisition agreement. Bookmark this page for streamlined access to verified financial filings, therapy approval timelines, and material event disclosures that shape PNT's growth trajectory.
Lantheus and POINT Biopharma announced that the FDA has granted Fast Track designation for 177Lu-PNT2002, a treatment for metastatic castration resistant prostate cancer (mCRPC). This designation aims to facilitate the drug's development and review process due to the significant unmet medical need in this area. The therapy combines a PSMA-targeted ligand with a beta-emitting radioisotope. Both companies emphasized the importance of this milestone, with Lantheus expressing optimism about working closely with the FDA to advance the therapy. The ongoing Phase 3 SPLASH trial, which assesses the efficacy of 177Lu-PNT2002, has completed enrollment, with top-line results expected in the second half of 2023. Lantheus holds exclusive worldwide commercialization rights for this product.
FAQ
What is the market cap of Point Biopharma Global (PNT)?
